Literature DB >> 22859716

Zeroing in on ROS1 rearrangements in non-small cell lung cancer.

Magda Stumpfova1, Pasi A Jänne.   

Abstract

Rimkunas and colleagues report on the development and validation of an immunohistochemical assay evaluating non-small cell lung cancers (NSCLC) for the presence of ROS1 fusions. The diagnostic was validated in a screen of 556 NSCLCs, identifying 9 (1.6%) tumors with oncogenic ROS1 rearrangements. These patients are candidates for ROS1-targeted therapies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22859716     DOI： 10.1158/1078-0432.CCR-12-1812

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Activated RET and ROS: two new driver mutations in lung adenocarcinoma.

Authors:  Marc Bos; Masyar Gardizi; Hans-Ulrich Schildhaus; Reinhard Buettner; Juergen Wolf
Journal:  Transl Lung Cancer Res       Date:  2013-04

2.  Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.

Authors:  Xingnan Zheng; Kan He; Lin Zhang; Jian Yu
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

3.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

4.  Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Authors:  Jim Sang; Jaime Acquaviva; Julie C Friedland; Donald L Smith; Manuel Sequeira; Chaohua Zhang; Qin Jiang; Liquan Xue; Christine M Lovly; John-Paul Jimenez; Alice T Shaw; Robert C Doebele; Suqin He; Richard C Bates; D Ross Camidge; Stephan W Morris; Iman El-Hariry; David A Proia
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

Review 5.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  Oncologist       Date:  2013-06-28

Review 6.  Other signalization targets.

Authors:  Nicolas Girard
Journal:  Target Oncol       Date:  2013-01-10       Impact factor: 4.493

7.  Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Lola Luo; Kun He; Ingrid Fran; Steven Lemery; Richard Pazdur
Journal:  Oncologist       Date:  2016-06-21

8.  A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features.

Authors:  Jianya Zhou; Jing Zhao; Jing Zheng; Mei Kong; Ke Sun; Bo Wang; Xi Chen; Wei Ding; Jianying Zhou
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

9.  Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell.

Authors:  Jing Zhao; Jing Zheng; Mei Kong; Jianya Zhou; Wei Ding; Jianying Zhou
Journal:  Oncotarget       Date:  2016-11-08

10.  Functional significance of U2AF1 S34F mutations in lung adenocarcinomas.

Authors:  Mohammad S Esfahani; Luke J Lee; Young-Jun Jeon; Ryan A Flynn; Henning Stehr; Angela B Hui; Noriko Ishisoko; Eric Kildebeck; Aaron M Newman; Scott V Bratman; Matthew H Porteus; Howard Y Chang; Ash A Alizadeh; Maximilian Diehn
Journal:  Nat Commun       Date:  2019-12-13       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.